# "IL-1β Blockade to Prevent Immunothrombosis in Recipients of a Pancreatic Organ"

> **NCT07503834** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Nantes University Hospital** · enrollment: 15 (estimated)

## Conditions studied

- Pancreatic Transplant

## Interventions

- **DRUG:** Anakinra 100Mg/0.67Ml Inj Syringe

## Key facts

- **NCT ID:** NCT07503834
- **Lead sponsor:** Nantes University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-01
- **Primary completion:** 2028-11-01
- **Final completion:** 2029-11-01
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2026-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07503834

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07503834, ""IL-1β Blockade to Prevent Immunothrombosis in Recipients of a Pancreatic Organ"". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT07503834. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*